HDL and Reverse Cholesterol Transport

Area of Science:

• Cardiovascular Medicine
• Biochemistry
• Molecular Biology

Background:

• Atherosclerosis, driven by cholesterol-rich foam cells, is a leading global cause of death.
• High-density lipoprotein (HDL)-mediated cholesterol efflux is a critical step in reverse cholesterol transport (RCT) and a potential antiatherogenic target.
• Therapeutic strategies targeting HDL cholesterol have faced challenges due to inconsistent associations with cardiovascular disease risk and RCT function.

Purpose of the Study:

• To review the mechanisms of RCT and reasons for the inconsistency between HDL cholesterol levels and cardiovascular disease risk.
• To highlight conditions where impaired HDL function or RCT contributes to vascular disease.
• To emphasize the need for further research into HDL functionality for cardiovascular disease prevention and treatment.

Main Methods:

• Literature review summarizing current understanding of RCT mechanisms.
• Analysis of factors contributing to the disconnect between HDL cholesterol levels and RCT function.
• Identification of clinical conditions linked to impaired HDL function and vascular disease.

Main Results:

• The relationship between HDL cholesterol levels and actual RCT function is inconsistent.
• Impaired HDL functionality and RCT are implicated in the progression of vascular disease.
• Current methods for measuring HDL's role in RCT may not fully capture its atheroprotective capacity.

Conclusions:

• Despite past disappointments, HDL functionality remains a promising area for cardiovascular disease intervention.
• Understanding the nuances of HDL function in RCT is crucial for developing effective antiatherogenic therapies.
• Further investigation into HDL's role in reverse cholesterol transport is warranted to improve cardiovascular disease prevention and treatment strategies.